EuCorVac-19

EuCorVac-19
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular

EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.[1][2][3][4]

Clinical trials

Phase I/II

EuBiologics Co., Ltd started the study on February 23, 2021.[5] The study is called "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults"[5] As of April 26, 2021, the trial is ongoing and participants are being accepted. It has an expected primary completion date of March 2022. The study is expected to be completed in January of 2023

References

  1. ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". Business Wire. 21 January 2021. Retrieved 17 April 2021.
  2. ^ Moon-hee, Choi (21 January 2021). "EuBiologics Wins Approval on Clinical Trial of COVID-19 Vaccine 'EuCOVAC-19'". Business Korea. Retrieved 17 April 2021.
  3. ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". EuBiologics. 21 January 2021. Retrieved 17 April 2021.
  4. ^ "Firm looks to build vaccine manufacturing plant in PH". ABS-CBN News. 12 April 2021. Retrieved 17 April 2021.
  5. ^ a b "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.{{cite web}}: CS1 maint: url-status (link)

Media files used on this page

WHO Rod.svg
The rod of Asclepius as depicted in the WHO logo.
SARS-CoV-2 (Wikimedia colors).svg
Author/Creator: Geraki, Licence: CC BY-SA 4.0
SARS-CoV-2 logo in Wikimedia colors
Sida-aids.png
Author/Creator: User:FoeNyx © 2004 (artistic illustration), Licence: CC-BY-SA-3.0
VIH - HIV / SIDA - AIDS viruses.
Scholia logo.svg
Author/Creator: Lars Willighagen, Licence: CC BY-SA 4.0
SVG remake of proposal for Scholia logo (File:Scholia logo.png by User:Theklan).
SARS-CoV-2 (CDC-23312).png
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV). Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. This virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
Syringe with Green Fluid.jpg
Author/Creator: Andres Rueda, Licence: CC BY 2.0
The following is the author's description of the photograph quoted directly from the photograph's Flickr page.
"Just wanted to test something with my ink refiller syringe. Filled with a oral-b mouthwash to give the greenish-blueish Max Payne valkyr effect. "